跳至主要内容

Primary Care Practitioners’ Views on the Use of Proton Pump Inhibitors Associated with Alginate-Antacids for Better Gastroesophageal Reflux Disease Symptom Control: Results of a National Survey in Spain

Read full paper at:
http://www.scirp.org/journal/PaperInformation.aspx?PaperID=50835#.VE3DAFfHRK0

Background: Gastroesophageal reflux disease (GERD) is a prevalent disease in Western countries. Despite effective treatment modalities, in some patients total symptom control is not achieved in clinical practice. A cross-sectional study was designed to assess primary care practitioners’ views on the effectiveness of proton pump inhibitors (PPI) as monotherapy in the control of the most common symptoms of GERD (heartburn and regurgitation), as well as to determine the level of implementation of the “combined therapy” (PPI + alginate-antacids). Methods: A questionnaire on different aspects of the management of GERD was completed by 1491 primary care physicians. The questionnaire was composed of 11 close-ended questions with one-choice answer, with a total of 52 items, covering the main data from patients presenting with GERD. Results: Treatment with PPI alone was mostly considered insufficient for the control of GERD symptoms. The combined treatment of PPI + alginate-antacids was used for 37% and 21% of physicians for treating heart-burn and regurgitation, respectively. A better control of symptoms, an increase in the onset of action and to reduce nocturnal acid breakthrough were the most frequently argued reasons for the use of PPI + alginate-antacids. A high percentage of participants believed that treatment with PPI alone was insufficient for the control of symptoms and 39.8% of physicians reported the persistence of heartburn, 38.6% the persistence of regurgitation and 43.2% the persistence of epigastric discomfort in more than 25% of their patients treated with PPI as monotherapy. The most common schedule for the use of the antacid medication was on demand. Conclusions: Spanish primary care physicians consider that a high proportion of GERD patients continue to suffer from symptoms during PPI treatment alone. Ondemand “combined therapy” (PPI + antacid) is considered an efficient option to control reflux symptoms still troublesome in patients with PPI treatment alone.
Cite this paper
Argila, C. , Belinchón, M. and Martínez, A. (2014) Primary Care Practitioners’ Views on the Use of Proton Pump Inhibitors Associated with Alginate-Antacids for Better Gastroesophageal Reflux Disease Symptom Control: Results of a National Survey in Spain. Open Journal of Gastroenterology, 4, 335-345. doi: 10.4236/ojgas.2014.410048. 
 

[1] Boeckxstaens, G.E. (2009) Emerging Drugs for Gastroesophageal Reflux Disease. Expert Opinion on Emerging Drugs, 14, 481-491.
http://dx.doi.org/10.1517/14728210903133807
[2] Dent, J., El-Serag, H.B., Wallander, M.A. and Johansson, S. (2005) Epidemiology of Gastro-Oesophageal Reflux Disease: A Systematic Review. Gut, 54, 710-717.
http://dx.doi.org/10.1136/gut.2004.051821
[3] El-Serag, H.B. (2007) Time Trends of Gastroesophageal Reflux Disease: A Systematic Review. Clinical Gastroenterology and Hepatology, 5, 17-26.
http://dx.doi.org/10.1016/j.cgh.2006.09.016
[4] Peery, A.F., Dellon, E.S., Lund, J., Crockett, S.D., McGowan, C.E., Bulsiewicz, W.J., Gangarosa, L.M., Thiny, M.T., Stizenberg, K., Morgan, D.R., Ringel, Y., Kim, H.P., Dacosta DiBonaventura, M., Carroll, C.F., Allen, J.K., Cook, S.F., Sandler, R.S., Kappelman, M.D. and Shaheen, N.J. (2012) Burden of Gastrointestinal Disease in the United States: 2012 Update. Gastroenterology, 143, 1179-1187.
http://dx.doi.org/10.1053/j.gastro.2012.08.002
[5] Rosemurgy, A.S., Donn, N., Paul, H., Luberice, K. and Ross, S.B. (2011) Gastroesophageal Reflux Disease. Surgical Clinics of North America, 91, 1015-1029.
http://dx.doi.org/10.1016/j.suc.2011.06.004
[6] Lenglinger, J., Riegler, M., Cosentini, E., Asari, R., Mesteri, I., Wrba, F. and Schoppmann, S.F. (2012) Review on the Annual Cancer Risk of Barrett’s Esophagus in Persons with Symptoms of Gastroesophageal Reflux Disease. Anticancer Research, 32, 5465-5473.
[7] Belhocine, K. and Galmiche, J.P. (2009) Epidemiology of the Complications of Gastroesophageal Reflux Disease. Digestive Diseases, 27, 7-13.
http://dx.doi.org/10.1159/000210097
[8] Liker, H., Hungin, A.P. and Wiklund, I. (2005) Management of Reflux Disease in Primary Care: The Patient Perspective. Journal of the American Board of Family Practice, 18, 393-400.
http://dx.doi.org/10.3122/jabfm.18.5.393
[9] Tack, J., Becher, A., Mulligan, C. and Johnson, D.A. (2012) Systematic Review: The Burden of Disruptive Gastro-Oesophageal Reflux Disease on Health-Related Quality of Life. Alimentary Pharmacology & Therapeutics, 35, 1257-1266.
http://dx.doi.org/10.1111/j.1365-2036.2012.05086.x
[10] Kennedy, T. and Jones, R. (2000) The Prevalence of Gastro-Oesophageal Reflux Symptoms in a UK Population and the Consultation Behaviour of Patients with These Symptoms. Alimentary Pharmacology & Therapeutics, 14, 1589-1594.
http://dx.doi.org/10.1046/j.1365-2036.2000.00884.x
[11] Bruley Des Varannes, S., Marek, L., Humeau, B., Lecasble, M. and Colin, R. (2006) Gastroesophageal Reflux Disease in Primary Care: Prevalence, Epidemiology and Quality of Life of Patients. Gastroentérologie Clinique et Biologique, 30, 364-370.
http://dx.doi.org/10.1016/S0399-8320(06)73189-X
[12] Hungin, A.P., Hill, C. and Raghunath, A. (2009) Systematic Review: Frequency and Reasons for Consultation for Gastro-Oesophageal Reflux Disease and Dyspepsia. Alimentary Pharmacology & Therapeutics, 30, 331-342.
http://dx.doi.org/10.1111/j.1365-2036.2009.04047.x
[13] Castell, D.O., Murray, J.A., Tutuian, R., Orlando, R.C. and Arnold, R. (2004) Review Article: The Pathophysiology of Gastro-Oesophageal Reflux Disease—Oesophageal Manifestations. Alimentary Pharmacology & Therapeutics, 20, 14-25.
http://dx.doi.org/10.1111/j.1365-2036.2004.02238.x
[14] Fass, R., Shapiro, M., Dekel, R. and Sewell, J. (2005) Systematic Review: Proton-Pump Inhibitor Failure in Gastro-Oesophageal Reflux Disease—Where Next? Alimentary Pharmacology & Therapeutics, 22, 79-94.
http://dx.doi.org/10.1111/j.1365-2036.2005.02531.x
[15] Dekel, R., Morse, C. and Fass, R. (2004) The Role of Proton Pump Inhibitors in Gastro-Oesophageal Reflux Disease. Drugs, 64, 277-295.
http://dx.doi.org/10.2165/00003495-200464030-00004
[16] Miner Jr., P.B. (2006) Review Article: Physiologic and Clinical Effects of Proton Pump Inhibitors on Non-Acidic and Acidic Gastro-Oesophageal Reflux. Alimentary Pharmacology & Therapeutics, 23, 25-32.
http://dx.doi.org/10.1111/j.1365-2036.2006.02802.x
[17] Sifrim, D. and Zerbib, F. (2012) Diagnosis and Management of Patients with Reflux Symptoms Refractory to Proton Pump Inhibitors. Gut, 61, 1340-1354.
http://dx.doi.org/10.1136/gutjnl-2011-301897
[18] Hrelja, N. and Zerem, E. (2011) Proton Pump Inhibitors in the Management of Gastroesophageal Reflux Disease. Medicinski Arhiv, 65, 52-55.
[19] Frazzoni, M., Piccoli, M., Conigliaro, R., Manta, R., Frazzoni, L. and Melotti, G. (2013) Refractory Gastroesophageal Reflux Disease as Diagnosed by Impedance-pH Monitoring Can Be Cured by Laparoscopic Fundoplication. Surgical Endoscopy, 27, 2940-2946.
http://dx.doi.org/10.1007/s00464-013-2861-3
[20] Dean, B.B., Gano Jr., A.D., Knight, K., Ofman, J.J. and Fass, R. (2004) Effectiveness of Proton Pump Inhibitors in Nonerosive Reflux Disease. Clinical Gastroenterology and Hepatology, 2, 656-664.
http://dx.doi.org/10.1016/S1542-3565(04)00288-5
[21] Tytgat, G.N., McColl, K., Tack, J., Holtmann, G., Hunt, R.H., Malfertheiner, P., Hungin, A.P. and Batchelor, H.K. (2008) New Algorithm for the Treatment of Gastro-Oesophageal Reflux Disease. Alimentary Pharmacology & Therapeutics, 27, 249-256.
http://dx.doi.org/10.1111/j.1365-2036.2007.03565.x
[22] Dettmar, P.W., Hampson, F.C., Jain, A., Choubey, S., Little, S.L. and Baxter, T. (2006) Administration of Alginate Based Gastric Reflux Suppressant on the Bioavailability of Omeprazole. Indian Journal of Medical Research, 123, 517-524.
[23] DeVault, K.R. and Castell, D.O. (2005) Updated Guidelines for the Diagnosis and Treatment of Gastroesophageal Reflux Disease. American Journal of Gastroenterology, 100, 190-200.
http://dx.doi.org/10.1111/j.1572-0241.2005.41217.x
[24] Dorval, E., Rey, J.F., Soufflet, C., Halling, K. and Barthélemy, P. (2011) Perspectives on Gastroesophageal Reflux Disease in Primary Care: The REFLEX Study of Patient-Physician Agreement. BMC Gastroenterology, 11, 25.
http://dx.doi.org/10.1186/1471-230X-11-25
[25] Ferrús, J.A., Zapardiel, J. and Sobreviela, E., SYMPATHY I Study Group (2009) Management of Gastroesophageal Reflux Disease in Primary Care Settings in Spain: SYMPATHY I Study. European Journal of Gastroenterology & Hepatology, 21, 1269-1278.
http://dx.doi.org/10.1097/MEG.0b013e32832a7d9b
[26] Bell, N.J.V., Burget, D., Howden, C.W., Wilkinson, J. and Hunt, R.H. (1992) Appropriate Acid Suppression for the Management of Gastro-Oesophageal Disease. Digestion, 51, 59-67.
http://dx.doi.org/10.1159/000200917
[27] Manabe, N., Haruma, K., Ito, M., Takahashi, N., Takasugi, H., Wada, Y., Nakata, H., Katoh, T., Miyamoto, M. and Tanaka, S. (2012) Efficacy of Adding Sodium Alginate to Omeprazole in Patients with Nonerosive Reflux Disease: A Randomized Clinical Trial. Diseases of the Esophagus, 25, 373-380.
http://dx.doi.org/10.1111/j.1442-2050.2011.01276.x
[28] Bell, N.J. and Hunt, R.H. (1992) Role of Gastric Acid Suppression in the Treatment of Gastro-Oesophageal Reflux Disease. Gut, 33, 118-124.
http://dx.doi.org/10.1136/gut.33.1.118
[29] Chey, W.D., Nody, R.R. and Izat, E. (2010) Patient and Physician Satisfaction with Proton Pump Inhibitors (PPIs): Are There Opportunities for Improvement? Digestive Diseases and Sciences, 55, 3415-3422.
http://dx.doi.org/10.1007/s10620-010-1209-2
[30] Van Zanten, S.J., Henderson, C. and Hughes, N. (2012) Patient Satisfaction with Medication for Gastroesophageal Reflux Disease: A Systematic Review. Canadian Journal of Gastroenterology, 26, 196-204.
[31] Chey, W.D., Mody, R.R., Wu, E.Q., Chen, L., Kothari, S., Persson, B., Beaulieu, N. and Lu, M. (2009) Treatment Patterns and Symptom Control in Patients with GERD: US Community-Based Survey. Current Medical Research and Opinion, 25, 1869-1878.
http://dx.doi.org/10.1185/03007990903035745
[32] Kahrilas, P.J., McColl, K., Fox, M., O’Rourke, L., Sifrim, D., Smout, A.J. and Boeckxstaens, G. (2013) The Acid Pocket: A Target for Treatment in Reflux Disease? American Journal of Gastroenterology, 108, 1058-1064.
http://dx.doi.org/10.1038/ajg.2013.132
[33] Katz, P.O., Gerson, L.B. and Vela, M.F. (2013) Guidelines for the Diagnosis and Management of Gastroesophageal Reflux Disease. American Journal of Gastroenterology, 108, 308-328.
http://dx.doi.org/10.1038/ajg.2012.444
[34] Tran, T., Lowry, A.M. and El-Serag, H.B. (2007) Meta-Analysis: The Efficacy of Over-the-Counter Gastro-Oesophageal Reflux Disease Therapies. Alimentary Pharmacology & Therapeutics, 25, 143-153.
[35] Fennerty, M.B., Finke, K.B., Kushner, P.R., Peura, D.A., Record, L., Riley, L., Ruoff, G.E., Simonson, W. and Wright, W.L. (2009) Short- and Long-Term Management of Heartburn and Other Acid-Related Disorders: Development of an Algorithm for Primary Care Providers. Journal of Family Practice, 58, S1-S12.                                                eww141027lx
标签：

评论

发表评论

此博客中的热门博文

A Comparison of Methods Used to Determine the Oleic/Linoleic Acid Ratio in Cultivated Peanut (Arachis hypogaea L.)

Cultivated peanut ( Arachis hypogaea L.) is an important oil and food crop. It is also a cheap source of protein, a good source of essential vitamins and minerals, and a component of many food products. The fatty acid composition of peanuts has become increasingly important with the realization that oleic acid content significantly affects the development of rancidity. And oil content of peanuts significantly affects flavor and shelf-life. Early generation screening of breeding lines for high oleic acid content greatly increases the efficiency of developing new peanut varieties. The objective of this study was to compare the accuracy of methods used to classify individual peanut seed as high oleic or not high oleic. Three hundred and seventy-four (374) seeds, spanning twenty-three (23) genotypes varying in oil composition (i.e. high oleic (H) or normal/not high oleic (NH) inclusive of all four peanut market-types (runner, Spanish, Valencia and Virginia), were individually tested ...
发表评论
阅读全文

Location Optimization of a Coal Power Plant to Balance Costs against Plant’s Emission Exposure

Fuel and its delivery cost comprise the biggest expense in coal power plant operations. Delivery of electricity from generation to consumers requires investment in power lines and transmission grids. Placing a coal power plant or multiple power plants near dense population centers can lower transmission costs. If a coalmine is nearby, transportation costs can also be reduced. However, emissions from coal plants play a key role in worsening health crises in many countries. And coal upon combustion produces CO 2 , SO 2 , NO x , CO, Metallic and Particle Matter (PM10 & PM2.5). The presence of these chemical compounds in the atmosphere in close vicinity to humans, livestock, and agriculture carries detrimental health consequences. The goal of the research was to develop a methodology to minimize the public’s exposure to harmful emissions from coal power plants while maintaining minimal operational costs related to electric distribution losses and coal logistics. The objective was...
发表评论
阅读全文

Evaluation of the Safety and Efficacy of Continuous Use of a Home-Use High-Frequency Facial Treatment Appliance

At present, many home-use beauty devices are available in the market. In particular, many products developed for facial treatment use light, e.g., a flash lamp or a light-emitting diode (LED). In this study, the safety of 4 weeks’ continuous use of NEWA TM , a high-frequency facial treatment appliance, every alternate day at home was verified, and its efficacy was evaluated in Japanese individuals with healthy skin aged 30 years or older who complained of sagging of the facial skin.  Transepidermal water loss (TEWL), melanin levels, erythema levels, sebum secretion levels, skin color changes and wrinkle improvement in the facial skin were measured before the appliance began to be used (study baseline), at 2 and 4 weeks after it had begun to be used, and at 2 weeks after completion of the 4-week treatment period (6 weeks from the study baseline). In addition, data obtained by subjective evaluation by the subjects themselves on a visual analog scale (VAS) were also analyzed. Fur...
发表评论
阅读全文